- Home
- EHI vs CVRX Comparison
EHI vs CVRX Comparison
Compare EHI & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- CVRX
- Stock Information
- Founded
- EHI 2003
- CVRX 2000
- Country
- EHI United States
- CVRX United States
- Employees
- EHI N/A
- CVRX N/A
- Industry
- EHI Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EHI Finance
- CVRX Health Care
- Exchange
- EHI Nasdaq
- CVRX Nasdaq
- Market Cap
- EHI 194.8M
- CVRX 189.0M
- IPO Year
- EHI N/A
- CVRX 2021
- Fundamental
- Price
- EHI $6.61
- CVRX $7.85
- Analyst Decision
- EHI
- CVRX Buy
- Analyst Count
- EHI 0
- CVRX 7
- Target Price
- EHI N/A
- CVRX $14.00
- AVG Volume (30 Days)
- EHI 44.5K
- CVRX 269.9K
- Earning Date
- EHI 01-01-0001
- CVRX 10-28-2025
- Dividend Yield
- EHI 11.54%
- CVRX N/A
- EPS Growth
- EHI N/A
- CVRX N/A
- EPS
- EHI N/A
- CVRX N/A
- Revenue
- EHI N/A
- CVRX $54,652,000.00
- Revenue This Year
- EHI N/A
- CVRX $11.32
- Revenue Next Year
- EHI N/A
- CVRX $18.58
- P/E Ratio
- EHI N/A
- CVRX N/A
- Revenue Growth
- EHI N/A
- CVRX 23.11
- 52 Week Low
- EHI $6.00
- CVRX $4.30
- 52 Week High
- EHI $7.75
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- EHI 56.40
- CVRX 56.23
- Support Level
- EHI $6.55
- CVRX $7.08
- Resistance Level
- EHI $6.65
- CVRX $7.86
- Average True Range (ATR)
- EHI 0.04
- CVRX 0.43
- MACD
- EHI -0.00
- CVRX 0.05
- Stochastic Oscillator
- EHI 73.33
- CVRX 84.92
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.